Chronic Leukemia

Introduction

A diagnosis of chronic leukemia can feel overwhelming, especially in the first weeks when there is a lot of new information to absorb. The word “chronic” itself raises questions: how long will treatment last, what will daily life look like, and what does the future hold? This guide is written for people who have already been diagnosed with chronic leukemia, or who are in the middle of having it confirmed, and want to understand the condition and the road ahead in clear, plain language.

Chronic leukemia is not one disease but a family of related blood cancers. The most important point to hold on to early is this: chronic leukemias usually develop slowly. Many people live with them for years, and modern treatments — particularly targeted oral medicines — have changed what life with chronic leukemia looks like. This article walks through what chronic leukemia is, how it is diagnosed, the main treatment paths your hematologist may discuss, what monitoring looks like long-term, and how people live well with the condition.

What Is Chronic Leukemia?

Leukemia is a cancer of the blood-forming cells in the bone marrow — the soft tissue inside your bones where blood cells are made. In leukemia, the bone marrow produces abnormal white blood cells that do not work properly and do not die off when they should. Over time these abnormal cells crowd out healthy blood cells, which can lead to anaemia (low red cells), infections (poorly functioning white cells), and bleeding or bruising (low platelets).

Leukemias are divided into two broad groups based on how quickly they progress: acute leukemias develop rapidly over weeks and need urgent treatment, while chronic leukemias develop slowly over months or years. They are also classified by the type of white blood cell involved — myeloid (the line that makes most white cells, red cells, and platelets) or lymphoid (the line that makes lymphocytes, a kind of immune cell).

The two main types of chronic leukemia are chronic myeloid leukemia and chronic lymphocytic leukemia. They are different diseases, with different causes, treatments, and outlooks, even though they share the same family name.

Chronic Myeloid Leukemia (CML)

CML affects the myeloid cell line. Almost all cases of CML are linked to a specific genetic change inside the bone marrow cells called the Philadelphia chromosome. This change creates a fusion gene known as BCR-ABL1, which produces an abnormal protein that drives uncontrolled cell growth.

• Chronic phase — the slowest, most stable phase, where most patients are diagnosed. Symptoms may be mild or absent.
• Accelerated phase — the disease becomes more active, with rising white cell counts and more symptoms.
• Blast phase (blast crisis) — the disease behaves like an acute leukemia and needs urgent, intensive treatment.

The discovery of BCR-ABL1 changed CML care dramatically. Targeted oral medicines called tyrosine kinase inhibitors (TKIs) now allow most people diagnosed in chronic phase to expect a near-normal life expectancy when treatment is taken consistently and monitored carefully.

Chronic Lymphocytic Leukemia (CLL)

CLL affects the lymphoid cell line, specifically a type of white cell called a B lymphocyte. Abnormal lymphocytes accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL and a closely related condition called small lymphocytic lymphoma (SLL) are considered the same disease in different locations — CLL when the abnormal cells are mostly in the blood, SLL when they are mostly in the lymph nodes.

CLL typically progresses very slowly. Many people diagnosed with early-stage CLL do not need treatment for years, and some never need it. When treatment is required, doctors today have several modern options including targeted oral therapies and monoclonal antibodies, which have largely replaced traditional chemotherapy as first-line treatment for most patients.

Other Chronic Leukemias

There are several less common chronic leukemias, including hairy cell leukemia, chronic myelomonocytic leukemia (CMML), large granular lymphocytic (LGL) leukemia, and prolymphocytic leukemia. These are rarer and are managed by specialist hematologists with treatments tailored to the specific subtype. The principles in this article apply broadly, but treatment specifics for these subtypes are decided case by case.

Causes and Risk Factors

Chronic leukemia is caused by genetic changes inside blood-forming cells in the bone marrow. These changes are almost always acquired during a person’s lifetime — they are not usually inherited from parents. The reasons these changes happen are not fully understood in most patients.

Known and suspected risk factors include:

• Age. Both CML and CLL become more common with age. CLL is rare under the age of 40.
• Sex. Both CML and CLL are slightly more common in men.
• Family history. A family history of CLL or related lymphoid cancers somewhat raises the risk of CLL. Family history is not a strong factor in CML.
• Previous radiation exposure. High-dose ionising radiation, such as that received during certain previous cancer treatments or major radiation accidents, raises the risk of CML.
• Certain chemicals. Long-term exposure to benzene and some industrial solvents has been linked to myeloid leukemias.
• Ethnic background. CLL is more common in people of European descent and less common in people of East Asian descent. CML rates are similar across populations.

It is important to know what chronic leukemia is not caused by. It is not contagious. It is not caused by stress, diet, mobile phones, or everyday lifestyle choices. Most people who develop chronic leukemia have no identifiable risk factor at all.

Signs and Symptoms

Many people with chronic leukemia have no symptoms at diagnosis and are discovered through a routine blood test. When symptoms do occur, they are often vague and develop gradually, which is one reason the disease is sometimes diagnosed late.

Common symptoms include:

• Persistent tiredness or weakness, often from anaemia
• Frequent or unusual infections
• Unexplained weight loss
• Drenching night sweats
• Painless swelling of lymph nodes in the neck, armpit, or groin (more typical of CLL)
• A feeling of fullness or discomfort on the left side of the abdomen, caused by an enlarged spleen (more typical of CML)
• Easy bruising, frequent nosebleeds, or bleeding gums
• Mild fevers without an obvious infection
• Bone or joint discomfort

If you have already been diagnosed, knowing these symptoms matters for a different reason: they can also signal that the disease is changing or progressing. New or worsening symptoms should always be discussed with your hematologist between scheduled visits.

Diagnosis

Diagnosing chronic leukemia involves a combination of blood tests, bone marrow examination, and genetic testing. The aim is not just to confirm the diagnosis but to determine the exact subtype, stage, and biological features — all of which guide treatment.

Complete Blood Count (CBC)

The CBC is usually the first test that raises suspicion. In CML, the white blood cell count is typically very high, often with a wide mix of immature and mature myeloid cells. In CLL, the lymphocyte count is high and persistent.

Peripheral Blood Smear

A drop of blood is examined under a microscope. The appearance of the abnormal cells gives important clues about which type of leukemia is present.

Flow Cytometry

This test uses markers on the surface of blood cells to identify them precisely. For CLL, flow cytometry can usually confirm the diagnosis from a blood sample alone, without needing a bone marrow biopsy.

Bone Marrow Aspiration and Biopsy

Cytogenetic and Molecular Testing

These tests look for specific genetic changes inside leukemia cells. In CML, doctors look for the Philadelphia chromosome and the BCR-ABL1 fusion gene. In CLL, doctors look for changes such as del(17p), TP53 mutations, and IGHV mutation status, which strongly affect treatment choice and outlook.

Staging in CLL

CLL is staged using systems called Rai (more common in the US) and Binet (more common in Europe). These systems classify the disease from early to advanced based on blood counts and whether lymph nodes, spleen, or liver are enlarged. Stage helps decide whether to treat now or to monitor.

Treatment and Management

Treatment for chronic leukemia depends on the type, the stage, the genetic features of the disease, your age and overall health, and your own preferences. The treatment landscape has changed significantly over the past two decades, particularly with the arrival of targeted oral therapies. Major societies such as the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Society of Hematology (ASH) publish regularly updated guidelines that shape how hematologists choose between options.

Active Monitoring (Watch and Wait)

For early-stage CLL without symptoms, current guidelines from major societies recommend active monitoring rather than immediate treatment. Studies have repeatedly shown that starting treatment early in asymptomatic CLL does not improve survival and exposes patients to side effects unnecessarily. Watch and wait usually involves blood tests and clinical review every 3 to 12 months. Treatment begins when there are clear signs of progression, such as falling blood counts, rapidly growing lymph nodes, significant symptoms, or an enlarging spleen.

Targeted Therapy

Targeted therapies are medicines that block specific molecules driving the cancer’s growth, rather than killing all rapidly dividing cells the way chemotherapy does. They are typically taken as pills and have transformed outcomes in chronic leukemia.

For CML, tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib block the abnormal BCR-ABL1 protein. Most people diagnosed in chronic phase achieve good disease control with a TKI, and many reach what is called a deep molecular response, where the BCR-ABL1 marker becomes very hard to detect. In selected patients who maintain a deep response for a sustained period, doctors may discuss attempting treatment-free remission — carefully stopping the TKI under close monitoring. This is not appropriate for everyone, and any decision to stop is made jointly with your hematologist.

For CLL, current guidelines have moved most patients toward targeted therapy as first-line treatment. The main classes are:

• BTK inhibitors (such as ibrutinib, acalabrutinib, zanubrutinib) — block a protein important to CLL cell survival.
• BCL-2 inhibitors (such as venetoclax) — help leukemia cells undergo natural cell death.
• PI3K inhibitors — used in selected situations after other treatments.

These are often combined with monoclonal antibodies (such as rituximab or obinutuzumab) that mark CLL cells for destruction by the immune system. The exact combination is chosen based on genetic features, fitness, and other health conditions.

Chemotherapy

Traditional chemotherapy has a smaller role than it did a decade ago, but it is still used in some situations — for example, in advanced CML, in the blast phase, in certain CLL patients when targeted therapy is unsuitable, or as part of preparation for a stem cell transplant. Chemotherapy may be given alone or combined with monoclonal antibodies (called chemoimmunotherapy).

Immunotherapy and Monoclonal Antibodies

Beyond the antibodies used in CLL combinations, more advanced immune-based treatments are being used in selected patients. These include bispecific antibodies and CAR-T cell therapy, an approach where a patient’s own immune cells are modified in a laboratory to recognise and attack leukemia cells. CAR-T is being studied and used in CLL that has not responded to multiple lines of treatment, and its role is expanding.

Allogeneic Stem Cell (Bone Marrow) Transplant

Because TKIs control CML so well, transplant is now considered mainly for CML that does not respond to multiple TKIs, for advanced-phase CML, or for certain high-risk situations. In CLL, transplant is reserved for younger, fitter patients with high-risk disease that has failed multiple targeted therapies. Decisions about transplant involve careful weighing of risks, donor matching, and timing, and are taken jointly by you, your hematologist, and a transplant specialist.

Splenectomy and Other Supportive Procedures

Occasionally, a very enlarged spleen causes severe symptoms or low blood counts that do not respond to medication. In selected cases, removing the spleen (splenectomy) or treating it with radiation may be considered. These are uncommon situations today, given the strength of medical treatments.

Lifestyle and Self-Management

Lifestyle choices do not cure chronic leukemia, but they support how well you tolerate treatment, reduce the risk of infections, and protect your long-term health. The aim is steady, realistic habits rather than dramatic changes.

• Nutrition. A balanced diet rich in vegetables, fruits, whole grains, and lean protein supports energy and immune function. Some people on treatment have specific food-safety needs (for example, avoiding raw or undercooked foods during periods of low blood counts) — your team will advise.
• Physical activity. Regular gentle to moderate activity, adjusted to how you feel, helps with fatigue, mood, and overall fitness. You do not need to push through severe tiredness.
• Infection prevention. Good hand hygiene, keeping up with recommended vaccinations (live vaccines are usually avoided — ask your team about timing), and avoiding contact with people who have active infections matter more than usual.
• Avoid smoking. Smoking worsens cardiovascular health, which matters because some treatments can stress the heart and circulation.
• Limit alcohol. Heavy drinking can interact with medicines and stress the liver, which is involved in processing many leukemia treatments.
• Medication adherence. For people on oral targeted therapy, taking the medicine consistently and at the same time of day is one of the single most important things you can do. Skipped doses can affect response.
• Sun protection. Some targeted therapies make the skin more sensitive to sun.
• Mental health. Living with a chronic cancer is hard. Counselling, peer support, and structured mindfulness or relaxation practices can genuinely help.

Monitoring and Treatment Response

Chronic leukemia is monitored carefully over time, both to track response to treatment and to catch any signs of progression early. The exact schedule depends on your type and phase of disease.

Monitoring in CML

CML response is tracked at three levels:

• Hematologic response — normal blood counts and no enlarged spleen.
• Cytogenetic response — reduction in cells carrying the Philadelphia chromosome.
• Molecular response — reduction in measurable BCR-ABL1 transcripts on a sensitive blood test (PCR).

Monitoring in CLL

In CLL, monitoring focuses on blood counts, symptoms, lymph node and spleen size, and signs of complications such as anaemia or infections. Specific imaging or bone marrow tests are repeated only when there are clinical reasons. Response to treatment is described in terms such as complete response, partial response, and measurable residual disease (MRD) — the latter is an increasingly important measure as deeper responses become achievable.

Risks and Complications

Chronic leukemia and its treatment carry several risks that your team will monitor for.

Complications of the Disease

• Anaemia — low red blood cells, causing tiredness and breathlessness.
• Infections — both because of the disease itself and because of treatment. People with CLL are particularly prone to certain bacterial and viral infections.
• Bleeding and bruising — from low platelets.
• Enlarged spleen or lymph nodes causing discomfort or pressure.
• Second cancers — people with CLL have a somewhat higher risk of skin cancers and certain other cancers. Regular skin checks are advised.
• Disease transformation — in CML, progression to accelerated or blast phase; in CLL, rarely, transformation into a more aggressive lymphoma (Richter transformation).
• Autoimmune complications — in CLL, the immune system can mistakenly attack red cells or platelets.

Side Effects of Treatment

Side effects vary by drug. Common patterns include:

• TKIs in CML — nausea, muscle cramps, fluid retention, rashes, low blood counts, and effects on the heart, lungs, or blood vessels depending on the specific TKI.
• BTK inhibitors in CLL — bruising, infections, joint aches, heart rhythm changes (especially atrial fibrillation), and high blood pressure.
• BCL-2 inhibitors — rapid breakdown of leukemia cells when starting (tumour lysis syndrome), requiring careful dose escalation and monitoring.
• Chemotherapy — hair loss, nausea, low blood counts, and infection risk.
• Monoclonal antibodies — infusion reactions, especially with the first dose.

Most side effects can be managed with dose adjustments, supportive medicines, or a temporary pause. Tell your team about new or worsening symptoms rather than waiting for the next appointment.

Living with Chronic Leukemia

For many people with chronic leukemia — particularly chronic-phase CML on a well-tolerated TKI, or early-stage CLL under monitoring — daily life looks much like it did before diagnosis, with the addition of regular blood tests, clinic visits, and medication routines. Others live with more day-to-day impact: fatigue, infection precautions, or side effects that need active management.

Common practical themes include:

• Work. Many people continue to work, sometimes with adjusted hours during the early months of treatment.
• Fertility and family planning. Some treatments can affect fertility, and pregnancy is generally not recommended while on certain medicines. If you are of reproductive age, discuss this with your hematologist before starting treatment — options such as sperm or egg preservation may be relevant.
• Vaccinations. Annual influenza vaccination and pneumococcal vaccination are usually recommended. Live vaccines are typically avoided. COVID-19 vaccination guidance is updated regularly — your team will advise based on current recommendations and your treatment.
• Dental and minor procedures. Tell any treating doctor or dentist about your diagnosis and medicines. Some procedures may need timing adjustments or antibiotic cover.
• Travel. Most patients can travel. Long flights, regions with specific infection risks, and access to medication supply during travel are worth planning around.
• Emotional health. Anxiety around test results (sometimes called “scanxiety” or “CBC anxiety”) is common. Support from family, peer groups, or a mental health professional can help.

Chronic Leukemia in Children

Chronic leukemias are uncommon in children. CLL is essentially not seen in childhood. CML occurs in children but is rare — it accounts for only a small percentage of all childhood leukemias. There is also a separate, distinct condition called juvenile myelomonocytic leukemia (JMML) that occurs in young children; despite the name it is biologically different from adult CML and is managed differently, often with stem cell transplant.

When CML does occur in children and adolescents, the same family of TKI medicines used in adults is generally the first-line treatment, with doses and choices adjusted for age and growth. Long-term considerations such as growth, bone development, fertility, and the duration of treatment over a lifetime are taken into account by pediatric hematology specialists. Care is provided in specialised pediatric or pediatric-adolescent hematology units with multidisciplinary input.

Outlook and Long-Term Follow-up

The outlook for chronic leukemia has improved dramatically. For CML diagnosed in chronic phase, life expectancy on a well-tolerated TKI is now close to that of the general population for many patients. For CLL, many people live with the disease for many years, sometimes never needing treatment at all, and modern targeted therapies have improved outcomes further for those who do.

That said, chronic leukemia is generally considered a long-term condition rather than something that is cured in the conventional sense. Even when responses are deep, lifelong follow-up is standard. Long-term care focuses on:

• Periodic blood tests and disease markers
• Watching for late side effects of long-term medication
• Screening for second cancers (skin checks in particular)
• Cardiovascular and bone health
• Vaccinations and infection prevention
• Supporting overall wellness and mental health

Some patients with CML who reach and maintain deep molecular responses may eventually be candidates for closely monitored treatment-free remission. Some patients with CLL achieve such deep responses with modern combinations that measurable disease falls below detection. These are real and meaningful developments, but they are decisions made in detailed discussion with your hematologist based on your specific situation.

When to Seek Urgent Care

Once you are living with chronic leukemia, certain symptoms should prompt prompt contact with your treatment team or an emergency department rather than waiting for the next appointment:

• A fever of 38°C (100.4°F) or higher, especially during active treatment or when blood counts are low
• Shaking chills, severe sweats, or signs of a serious infection
• Sudden shortness of breath or chest pain
• Unusual bleeding — nosebleeds that will not stop, blood in urine or stool, large new bruises
• Severe or sudden abdominal pain (especially on the left, where the spleen sits)
• Sudden severe headache, confusion, or weakness on one side of the body
• New, rapidly enlarging lymph nodes
• Severe reactions to a medication, such as widespread rash, swelling, or difficulty breathing

If in doubt, contact your team. Hematology units are used to fielding calls about new symptoms and will guide you on whether to come in.

Frequently Asked Questions

Is chronic leukemia curable?

For most people, chronic leukemia is best understood as a long-term condition that can be controlled rather than cured in the traditional sense. CML controlled with a TKI can stay in deep remission for years, and some patients can eventually attempt carefully monitored treatment-free remission. CLL is generally not cured but can be controlled for long periods. Allogeneic stem cell transplant is the one treatment with clear curative potential, but it is reserved for selected patients because of its risks.

Will I need treatment straight away?

Not always. Many people with early-stage CLL are monitored for months or years before any treatment is needed. CML is usually treated soon after diagnosis because TKIs work best when started early. The decision is individual and made with your hematologist.

Can I keep working?

Most people on stable oral targeted therapy continue to work. The early months of treatment, periods of dose adjustment, or infusion-based treatments may require some changes to schedule.

Is chronic leukemia hereditary? Should my children be tested?

Chronic leukemias are not strongly hereditary. There is a modest increase in CLL risk in close relatives of CLL patients, but routine screening of family members is not recommended. CML is not considered an inherited disease.

Can I have children after a diagnosis?

Many people can, but fertility considerations vary by treatment. Some medicines are unsafe during pregnancy. If you are of reproductive age, discuss family planning, contraception during treatment, and fertility preservation early with your hematologist.

What does “remission” mean in chronic leukemia?

Remission means the disease is under good control by clinical, laboratory, or molecular measures. In CML, doctors describe hematologic, cytogenetic, and molecular responses. In CLL, response is described as complete, partial, or by measurable residual disease. Remission does not always mean cure, but it usually means the disease is not actively causing problems.

Are blood transfusions needed often?

Most people with well-controlled chronic leukemia do not need regular transfusions. Transfusions may be needed during active treatment phases, when blood counts are very low, or in advanced disease.

How is chronic leukemia different from acute leukemia?

Acute leukemias develop quickly over days to weeks, cause severe symptoms, and need urgent intensive treatment, usually in hospital. Chronic leukemias develop slowly over months to years, often have few symptoms at first, and are managed largely on an outpatient basis.

Should I take supplements or alternative therapies?

Some supplements interact with leukemia medicines — St John’s wort and high-dose grapefruit products, for example, can interfere with TKIs. Always tell your hematologist about any supplements, herbal products, or alternative therapies you are using or considering.

Conclusion

Chronic leukemia is a serious diagnosis, but in many cases it is a manageable one. Understanding which type you have, what your specific genetic features look like, and what the current treatment options are gives you a foundation to make decisions alongside your hematology team. Modern targeted therapies have changed what living with chronic leukemia can look like — for many people, it now involves regular monitoring, daily oral medication, and an active life rather than long hospital stays. The path is not the same for everyone, and the right plan is one shaped around your disease, your overall health, and your priorities, in close partnership with your specialist team.